Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cancer Genetics Inc (CGIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,473
  • Shares Outstanding, K 27,750
  • Annual Sales, $ 29,120 K
  • Annual Income, $ -20,880 K
  • 36-Month Beta 1.28
  • Price/Sales 0.94
  • Price/Cash Flow N/A
  • Price/Book 1.48
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.83
  • Most Recent Earnings -0.16 on 08/14/17
  • Next Earnings Date 08/13/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.90 unch
on 06/22/18
1.16 -22.41%
on 05/23/18
-0.06 (-6.25%)
since 05/22/18
3-Month
0.82 +9.49%
on 05/10/18
1.90 -52.63%
on 03/23/18
-1.00 (-52.63%)
since 03/22/18
52-Week
0.82 +9.49%
on 05/10/18
4.25 -78.82%
on 07/06/17
-2.90 (-76.32%)
since 06/22/17

Most Recent Stories

More News
Cancer Genetics Strengthens Management Team with Appointment of Michael McCartney as Chief Commercial Officer

Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the appointment Michael McCartney as the Company's Chief...

CGIX : 0.90 (-9.09%)
Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Cancer Genetics, Inc. (CGIX)

Glancy Prongay & Murray LLP ("GPM") reminds investors of the June 4, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Cancer...

CGIX : 0.90 (-9.09%)
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Cancer Genetics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 4, 2018 / , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Cancer Genetics, Inc. ("Cancer Genetics" or ''the Company'')...

CGIX : 0.90 (-9.09%)
FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Cancer Genetics, Inc. (CGIX) and Lead Plaintiff Deadline - June 4, 2018

NEW YORK, NY / ACCESSWIRE / June 4, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Cancer Genetics, Inc. (''Cancer Genetics'' or the ''Company'')...

CGIX : 0.90 (-9.09%)
3-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Cancer Genetics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 1, 2018 / , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Cancer Genetics, Inc. ("Cancer Genetics" or ''the Company'')...

CGIX : 0.90 (-9.09%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cancer Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline - CGIX

NEW YORK, NY / ACCESSWIRE / June 1, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Cancer Genetics, Inc. ("Cancer Genetics" or the "Company") (NASDAQ: CGIX) and certain...

CGIX : 0.90 (-9.09%)
CANCER GENETICS LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 in Cancer Genetics, Inc. to Contact the Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Cancer Genetics, Inc. ("Cancer Genetics" or the "Company") (NASDAQ: CGIX) of the June 4, 2018 deadline to...

CGIX : 0.90 (-9.09%)
Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Cancer Genetics, Inc. (CGIX) and Encourages Investors to Contact the Firm Before June 4th

Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all persons or entities who purchased or...

CGIX : 0.90 (-9.09%)
MONDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Cancer Genetics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 31, 2018 / , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Cancer Genetics, Inc. ("Cancer Genetics" or ''the Company'')...

CGIX : 0.90 (-9.09%)
Safirstein Metcalf LLP Reminds Investors That A Class Action Has Been Filed Against Cancer Genetics, Inc. - CGIX

Safirstein Metcalf LLP, reminds investors that a class action lawsuit was filed in the U.S. District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise...

CGIX : 0.90 (-9.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade CGIX with:

Business Summary

Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company's tests target cancers, including hematological, urogenital, and HPV-associated...

See More

Key Turning Points

2nd Resistance Point 1.02
1st Resistance Point 0.96
Last Price 0.90
1st Support Level 0.87
2nd Support Level 0.84

See More

52-Week High 4.25
Fibonacci 61.8% 2.94
Fibonacci 50% 2.54
Fibonacci 38.2% 2.13
Last Price 0.90
52-Week Low 0.82

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar